tbuckley/cabot-search huggingface dataset:
Subarachnoid haemorrhage
Authors: Rustam Al-Shahi, Philip M White, Richard J Davenport, Kenneth W Lindsay
Journal: BMJ (2006)

<h3>Background</h3> Several studies have investigated the predictors of morbidity and mortality in Systemic sclerosis (SSc). However long-term follow-up data from inception cohorts of early SSc patients are limited. <h3>Objectives</h3> To identify predictors of morbidity and mortality in a single centre inception cohort of early SSc patients at long-term follow-up. <h3>Methods</h3> Our inception cohort comprised SSc patients who fulfilled the American College of Rheumatology criteria, were recruited within 12 months of disease onset and followed prospectively for at least 3 years. Clinical manifestations, laboratory and lung function tests were recorded for each patient at baseline and at 3rd and 6th years of follow up. Multivariate regression analysis and Cox proportional hazard models were used to identify predictors (clinical manifestations, laboratory and lung function tests at baseline) of morbidity and mortality in SSc, respectively. <h3>Results</h3> A total of 114 patients (96 female, mean age at diagnosis 48.1±13.5 years, 53 diffuse SSc subtype) were included in the study, from January 1997 to December 2012. All patients were followed for at least 3 years and 84 patients for at least 6 years. Twenty (17.5%) of 114 patients died during a mean follow up of 101.8±48.5 months. In multivariate regression analysis predictors for major SSc outcomes at 6 years were: diffuse subtype (OR: 6.2, p=0.015), anti-scl-70 positivity (OR: 3.9, p=0.05), esophageal involvement (OR: 6.5, p=0.017) and digital ulcers (OR: 8.6, p=0.003) at baseline for the development of pulmonary fibrosis (PF). The presence of digital ulcers at baseline was a predictor for the development of arrhythmias (OR: 3.7, p=0.05) and the presence of arrhythmias at baseline for the development of pulmonary hypertension (PH) (OR: 5.4, p=0.039). Cox proportional hazard models multivariate analysis revealed that independent predictors of mortality were: male gender (HR: 3.3, p=0.023), diffuse type (HR: 8.7, p=0.004), PF at baseline (HR: 2.7, p=0.05), PH based on echocardiography at baseline (HR: 12.7, p=0.001) FVC &lt;80% (HR: 2.74, p=0.042) and DLCO &lt;60% of predicted value at baseline (HR: 2.97, p=0.019). <h3>Conclusions</h3> Results from long-term follow-up data from a single centre inception cohort indicate that diffuse SSc subtype, anti-Scl-70 positivity, esophageal involvement and digital ulcers at baseline are independent predictors for the development of PF. Male gender, diffuse subtype, PF, PH and decreased FVC and DLCO at baseline are prognostic factors of mortality. <h3>Disclosure of Interest</h3> None declared
Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarkers in Children With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE
Authors: Leonard Bacharier, Daniel Jackson, Ian Pavord, Jorge Maspero, Xuezhou Mao, Dongfang Liu, Juby Jacob-Nara, Yamo Deniz, Elizabeth Laws, Leda Mannent, Nikhil Amin, Bolanle Akinlade, David Lederer, Megan Hardin
Journal: Journal of Allergy and Clinical Immunology (2022)
Methodological caveats regarding “Novel insights into surfactant protein C trafficking revealed through the study of a pathogenic mutant”
Authors: Surafel Mulugeta, Timothy E. Weaver, Michael F. Beers
Journal: European Respiratory Journal (2022)

<b>The manuscript by Dickens and co-workers examines biosynthesis of surfactant protein C (SP-C). However, limitations in the model system used and bioproperties of SP-C necessitate further studies to support many of the stated conclusions.</b>https://bit.ly/3ACTRRl
Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas: Erratum
Authors: Lili Li, Juan Xu, Guohua Qiu, Jianming Ying, Zhenfang Du, Tingxiu Xiang, Kai Yau Wong, Gopesh Srivastava, Xiao-Feng Zhu, Tony S Mok, Anthony TC Chan, Francis KL Chan, Richard F Ambinder, Qian Tao
Journal: Theranostics (2022)

[This corrects the article DOI: 10.7150/thno.20893.].
c-FLIP: A Key Regulator of Colorectal Cancer Cell Death
Authors: Timothy R. Wilson, Kirsty M. McLaughlin, Miranda McEwan, Hidekazu Sakai, Katherine M.A. Rogers, Kelly M. Redmond, Patrick G. Johnston, Daniel B. Longley
Journal: Cancer Research (2007)

Abstract c-FLIP is an inhibitor of apoptosis mediated by the death receptors Fas, DR4, and DR5 and is expressed as long (c-FLIPL) and short (c-FLIPS) splice forms. We found that small interfering RNA (siRNA)-mediated silencing of c-FLIP induced spontaneous apoptosis in a panel of p53 wild-type, mutant, and null colorectal cancer cell lines and that this apoptosis was mediated by caspase-8 and Fas-associated death domain. Further analyses indicated the involvement of DR5 and/or Fas (but not DR4) in regulating apoptosis induced by c-FLIP siRNA. Interestingly, these effects were not dependent on activation of DR5 or Fas by their ligands tumor necrosis factor–related apoptosis-inducing ligand and FasL. Overexpression of c-FLIPL, but not c-FLIPS, significantly decreased spontaneous and chemotherapy-induced apoptosis in HCT116 cells. Further analyses with splice form–specific siRNAs indicated that c-FLIPL was the more important splice form in regulating apoptosis in HCT116, H630, and LoVo cells, although specific knockdown of c-FLIPS induced more apoptosis in the HT29 cell line. Importantly, intratumoral delivery of c-FLIP–targeted siRNA duplexes induced apoptosis and inhibited the growth of HCT116 xenografts in BALB/c severe combined immunodeficient mice. In addition, the growth of c-FLIPL–overexpressing colorectal cancer xenografts was more rapid than control xenografts, an effect that was significantly enhanced in the presence of chemotherapy. These results indicate that c-FLIP inhibits spontaneous death ligand–independent, death receptor–mediated apoptosis in colorectal cancer cells and that targeting c-FLIP may have therapeutic potential for the treatment of colorectal cancer. [Cancer Res 2007;67(12):5754–62]
Osmium: An Appraisal of Environmental Exposure
Authors: Ivan C. Smith, Bonnie L. Carson, Thomas L. Ferguson
Journal: Environmental Health Perspectives (1974)

In the U.S., the chief source of new osmium is copper refining, where this metal is produced as a byproduct. Probably less than 10% of the osmium in the original copper ore is recovered, and 1000–3000 oz troy of osmium is lost each year to the environment as the toxic, volatile tetroxide from copper smelters. In 1971, about 2000 oz troy of osmium was domestically refined, most of which was from secondary sources. An additional 4169 oz troy of osmium was toll-refined. Major uses for osmium tetroxide identified are for catalysis, especially in steroid synthesis, and for tissue staining. Minor uses of osmium metal are for electrical contacts and for imparting hardness to alloys for mechanical pivots, etc. Unreclaimed osmium tetroxide that reaches wastewater streams is probably rapidly reduced by organic matter to nontoxic osmium dioxide or osmium metal, which would settle out in the sediment of the water course. Waste osmium metal, itself innocuous and chemically resistant, would be oxidized to the toxic tetroxide if incinerated.Because of the small amounts used and their wide dispersal, the amounts of osmium tetroxide in wastewater and air should pose no hazard to man or the environment. The chief acute toxic effects of osmium tetroxide are well known and include eye and respiratory-tract damage. Few data are available that provide information on possible effects of nonacute exposure resulting from environmental contamination by osmium. However, workers continually exposed to osmium tetroxide vapors (refiners and histologists) and rheumatoid arthritis patients who have received intra-articular injections of osmic acid solutions have shown no apparent damage from exposure to low levels of osmium.
Delayed Influenza Vaccine Availability for 2001-02 Season and Supplemental Recommendations of the Advisory Committee on Immunization Practices
Journal: JAMA (2001)

Manufacturer projections of vaccine distribution for the 2001-02 influenza season suggest that 49.8 million doses will be available for delivery by the end of October 2001; this is approximately 26 million fewer doses of influenza vaccine than were available by the end of October 1999 (75.8 million doses) (Figure 1). Manufacturers also project distribution of 27.3 million doses in November and December, bringing the cumulative projected total to 77.1 million doses, which is greater than in 2000 (70.4) and comparable with 1999 (76.8). Predictions of monthly vaccine distribution vary by manufacturer, and providers will probably receive vaccine on different schedule.
Correction
Journal: BMJ (1925)

THE West African Medical Staff List, revised up to the end of January, 1925, may be obtaiued from the Crown Agents for the Colonies, 4, Millbank, S.W.1.Three lists are provided, officers being classed in grades, according to colonies, and according to their qualificatiotis and setvices.MESSitS.W. HEFFER AND SONS, publishers and booksellers of Cambridge, have issued a catalogue of new and recent scientific books published by them, or of which they have copies for sale.It is arranged under suitable headings, ranging from mathematics and physics to physiology, anatomy, and medicine.It also contains a list of portraits of men of science the firm has for disposal, and a list of complete sets of journals which can be obtained from them.Copies of the catalogue can, we presume, be obtained from them at 4, Petty Cury, Cambridge.ON his retiremenL from the post of mnedical officer of health for Hornsey to take up a siwuilar appointment at Plymouth,
Altered distribution, activation and increased IL-17 production of mucosal-associated invariant T cells in patients with acute respiratory distress syndrome
Authors: Tae-Ok Kim, Ki-Jeong Park, Young-Nan Cho, Hye-Mi Jin, Young-Goun Jo, Hyo Shin Kim, Jae Kyun Ju, Hong-Joon Shin, Bo-Gun Kho, Seung-Jung Kee, Yong-Wook Park
Journal: Thorax (2022)

Objective Mucosal-associated invariant T (MAIT) cells are a subset of innate-like T cells that are engaged in a number of diseases, but their roles in acute respiratory distress syndrome (ARDS) are not fully examined yet. This study aimed to examine levels and functions of MAIT cells in patients with ARDS. Methods Peripheral blood samples from patients with ARDS (n=50) and healthy controls (HCs, n=50) were collected. Levels of MAIT cells, cytokines, CD69, programmed cell death-1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) were measured by flow cytometry. Results Circulating MAIT cell levels were significantly reduced in patients with ARDS than in HCs. MAIT cell levels were inversely correlated with disease severity and mortality. Cytokine production profiles in MAIT cells showed that percentages of interleukin (IL)-17 producing MAIT cell were significantly higher in patients with ARDS than in HCs. Patients with ARDS exhibited higher expression levels of CD69, PD-1 and LAG-3 in circulating MAIT cells. Moreover, levels of MAIT cells and expression levels of CD69, PD-1 and IL-17 in MAIT cells were higher in bronchoalveolar lavage fluid samples than in peripheral blood samples. Our in vitro experiments showed that MAIT cells triggered macrophages to produce proinflammatory cytokines such as tumour necrosis factor-α, IL-1β and IL-8. Conclusions This study demonstrates that circulating MAIT cells are numerically deficient in patients with ARDS. In addition, MAIT cells were found to be activated, migrate into lung, secrete IL-17 and then stimulate macrophages. These findings suggest that MAIT cells contribute to the worsening of inflammation in the lung of patients with ARDS.
<i>Announcement:</i>25th Anniversary of National Program of Cancer Registries, 1992–2017
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

This year marks the 25th anniversary of the Cancer Registries Amendment Act (Public Law 102-515), which established the National Program of Cancer Registries (NPCR) administered by CDC (1). NPCR collects high quality data on cancer occurrence (including the type, extent, and location of the cancer), type of initial treatment, and outcomes. NPCR supports cancer registries in 45 states, the District of Columbia, Puerto Rico, and U.S. Pacific Island jurisdictions, covering 96% of all cancers diagnosed in the United States.
Deaths
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genotype-Guided Dosing of Vitamin K Antagonists
Authors: Elizabeth A Koller, Jeffrey C Roche, James A Rollins
Journal: New England Journal of Medicine (2014)

To the Editor: Three articles in the December 12 issue 1-3 address pharmacogenetics and dosing of coumarin anticoagulants.Because it is more usual for elderly patients to have an international normalized ratio (INR) outside the targeted therapeutic range and to have frank bleeding, it would be of clinical interest to know whether the authors stratified patients by age and whether coexisting conditions or the use of concomitant medications contributed to any effects related to age. [4]][6] In addition, because the frequency of polymorphisms varies according to ethnic background, it would be of clinical interest to know the differential effects of coumarin anticoagulants in different populations. 7Last, because drug exposure may be a better determinant of drug metabolism than dosage, it would be of clinical value to know whether the authors had pharmacokinetic data. 8
27373 Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE SURE bimekizumab in moderate to severe plaque psoriasis phase 3 trial
Authors: Richard B. Warren, Matthias Augustin, Alice B. Gottlieb, Kristina Callis Duffin, Valerie Ciaravino, Christopher Cioffi, Luke Peterson, Andrew Blauvelt
Journal: Journal of the American Academy of Dermatology (2021)
Atrial fibrillation
Authors: A. Bradley, P. Sheridan
Journal: BMJ (2013)

A 67 year old woman presents with recent onset of “palpitations,” lethargy, and shortness of breath, usually related to exercise. She experiences a fluttering in her chest and has hypertension and type 2 diabetes. Atrial fibrillation is the commonest cardiac arrhythmia, increasing in frequency with age. It causes various symptoms including palpitations, lethargy, shortness of breath, and chest pain and increases the risk of stroke sixfold.1 It can be intermittent (paroxysmal) or continuous (persistent (>7 days to 1 year), longstanding persistent (>1 year), or permanent). Controlling symptoms is important, but reducing stroke risk is paramount. Consider: ### Initial assessment #### Box 1: Causes of atrial fibrillation
Colchicine for periodic peritonitis
Authors: H. A. Reimann
Journal: JAMA (1975)

† After 25 years of unsuccessful therapeutic trials, colchicine suppressed episodes of periodic peritonitis (recurrent polyserositis, familial Mediterranean fever) in most reported cases after 1972 and in 12 of 14 patients in this study. Dosage of 0.65 mg daily was continuous, but intermittent therapy timed in accordance with predicted episodes is under trial. Suppression of episodes by the drug serves as the only diagnostic test available. (<i>JAMA</i>231:64-66, 1975)
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
Authors: Mona Fiuzat, Carine E. Hamo, Javed Butler, William T. Abraham, Ersilia M. DeFilippis, Gregg C. Fonarow, Joann Lindenfeld, Robert J. Mentz, Mitchell A. Psotka, Scott D. Solomon, John R. Teerlink, Muthiah Vaduganathan, Orly Vardeny, John J.V. McMurray, Christopher M. O’Connor
Journal: Journal of the American College of Cardiology (2022)

With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction.
Geographic Variation in Colorectal Cancer Incidence Among Asian Americans: A Population-Based Analysis 2006–2016
Authors: Christina P. Wang, Jenny J. Lin, Shailja C. Shah, Michelle Kang Kim, Eric M. Montminy, Sheila D. Rustgi, Jordan J. Karlitz, Steven H. Itzkowitz
Journal: Clinical Gastroenterology and Hepatology (2022)
Awards, Appointments, Announcements
Journal: JNCI Journal of the National Cancer Institute (1992)

Awards, Appointments, Announcements JNCI: Journal of the National Cancer Institute, Volume 84, Issue 16, 19 August 1992, Pages 1236–1237, https://doi.org/10.1093/jnci/84.16.1236 Published: 19 August 1992
Klebsiella pneumoniae Liver Abscess With Intracerebral Hemorrhage
Authors: Tsai-Hung Yen, Chao-Hung Lai, Meng-Ko Tsai
Journal: Clinical Gastroenterology and Hepatology (2022)

A 58-year-old woman with diabetes without a history of hypertension presented with a 4-day history of fever and right upper abdominal pain. Abdominal computed tomography showed multiloculated peripherally enhanced cystic lesions of the left hepatic lobe (Figure A). Blood and abscess cultures yielded wild-type Klebsiella pneumoniae. Left proptosis, ophthalmoplegia, and conjunctival chemosis (Figure B) were observed on Day 5; visual acuity was "hand motion." Orbital computed tomography showed uveoscleral thickening and periorbital fat stranding (Figure C, arrows), and a 1-cm high-density hematoma of the left basal ganglia (Figure D, circle). Intravitreal ceftazidime and vancomycin were administered to the left eye on Days 5, 7, and 9. During 18 months of follow-up, the visual acuity of her left eye remained limited to light perception, but there were no other signs of stroke or orbital infection. K pneumoniae invasive syndrome is an emerging disease, especially in Asia, with gastrointestinal colonization being a common source. Eyes and central nervous system are the most frequent metastatic sites affected. Bacteremia is an independent risk factor for both ischemic and hemorrhagic stroke. K pneumoniae liver abscess often causes septic embolism and K pneumoniae bacteremia may increase the risk of intracerebral hemorrhage. Physicians should be aware that intracerebral hemorrhage may be a complication of K pneumoniae invasive syndrome. This study received assistance of the Department of Medical Education and Research, Taichung Armed Forces General Hospital. The authors thank Che-Min Lin, MD, I-Chen Tsai, MD, PhD, and Mr. Kai-Ti Chang, for their assistance (grant ID: TCAFGH-E-110042).
Erratum to: Adaptive Introgression Facilitates Adaptation to High Latitudes in European Aspen (Populus Tremula L.)
Authors: Martha Rendón-Anaya, Jonathan Wilson, Sæmundur Sveinsson, Aleksey Fedorkov, Joan Cottrell, Mark E S Bailey, Dainis Ruņǵis, Christian Lexer, Stefan Jansson, Kathryn M Robinson, Nathaniel R Street, Pär K Ingvarsson
Journal: Molecular Biology and Evolution (2022)
The 1996 JAMA Peer Reviewers
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Insomnia
Authors: Ann R. Punnoose, Robert M. Golub, Alison E. Burke
Journal: JAMA (2012)

InsomniaI nsomnia is a sleep disorder that includes trouble falling asleep, staying asleep, or waking too early, resulting in daytime impairment.It is a common problem, usually occurring along with other diseases or emotional stress (comorbid insomnia).It can also exist without other medical or mental health causes (primary insomnia).Long-standing (chronic) insomnia can lead to daytime consequences such as fatigue or sleepiness, difficulty with thinking, and mood impairments, which can interfere with performance at school and work.
Reply to In vivo confusion over in vivo conversion
Authors: Lei-Lei Wang, Chun-Li Zhang
Journal: Molecular Therapy (2022)

We strongly disagree with Dr. Gong Chen's criticisms of our recently published Cell paper 1 Wang L.L. Serrano C. Zhong X. Ma S. Zou Y. Zhang C.L. Revisiting astrocyte to neuron conversion with lineage tracing in vivo. Cell. 2021; 184: 5465-5481.e5416https://doi.org/10.1016/j.cell.2021.09.005 Google Scholar in his recent letter to the editor. 2 Chen G. In vivo confusion over in vivo conversion. Mol. Ther. 2021; 29: 3097-3098https://doi.org/10.1016/j.ymthe.2021.10.017 Google Scholar Limited astrocyte-to-neuron conversion in the mouse brain using NeuroD1 overexpressionLeib et al.Molecular TherapyFebruary 4, 2022In BriefThe central nervous system (CNS) is largely unable to generate new neurons to compensate for the loss of neurons caused by disease or injury. One potentially promising approach to replace CNS neurons is to convert resident astrocytes into neurons in situ by gene therapy. Conversion of astrocytes to neurons in vitro by overexpression of the transcription factor Pax6 was first reported nearly 20 years ago.1 Since then, multiple groups have reported astrocyte-to-neuron conversion in vitro and in vivo following various genetic manipulations. Full-Text PDF
Meaningful Response to TILs in NSCLC
Journal: Cancer Discovery (2021)

Preliminary data suggest that a tumor-infiltrating lymphocyte therapy called LN-145 may provide an option for patients with non-small cell lung cancer whose disease has progressed despite receiving other therapies, including PD-1 or PD-L1checkpoint inhibitors. Trial participants had an overall response rate of 21.4%, and the median duration of response had not been reached after 8.2 months of follow-up.